The best execution of the DuoStim strategy (double stimulation in the follicular and luteal phase of the same ovarian cycle) in patients who are poor ovarian responders

Yanqun Luo, Li Sun, Mei Dong, Xiqian Zhang, Li Huang, Xiulan Zhu, Yingqi Nong and Fenghua Liu

Abstract

Background: Patients found to be poor ovarian responders (POR) are a challenging patient population for any assisted reproduction technology. Despite attempts at various controlled ovarian stimulation schemes, reproductive outcomes in this patient population have not improved. In recent years, the DuoStim protocol (both follicular and luteal phase stimulation during the same menstrual cycle) has shown a potential for use in patients with POR.

Methods: This retrospective study reviewed the medical records of 304 women who were diagnosed as POR and underwent the DuoStim protocol. We compared follicular phase stimulation (FPS) data and luteal phase stimulation (LPS) data of the same patients. We also compared the effects of different trigger drugs including urine human chorionic gonadotropin (uHCG; 10,000 IU), recombinant human chorionic gonadotropin (rHCG; 250 μg), and gonadotropin-releasing hormone agonist (GnRH-a; 0.2 mg) at the FPS and LPS stages.

Results: POR undergoing the DuoStim protocol resulted in a significantly higher number of oocytes retrieved, normal fertilised oocytes, cleaved embryos, cryopreserved embryos, and good quality embryos at the LPS stage than at the FPS stage. Trigger drugs at the FPS stage did not affect the FPS stage data. Regardless of the stage, rHCG and GnRH-a yielded significantly more cryopreserved embryos and good quality embryos than uHCG.

Conclusion: The use of GnRH-a or rHCG as the trigger drug may be better than uHCG in both the FPS and LPS stages for POR undergoing the DuoStim protocol. This will increase the number of good quality embryos at the LPS stage. We found that the LPS stage results in more oocytes (and therefore more embryos) than the FPS stage.

Keywords: Ovulation induction, Luteal phase, Follicular phase, Cryopreservation, Gonadotropin-releasing hormone
Background

Poor ovarian responders (POR) are a challenging patient population in the field of assisted reproduction technology (ART). Despite attempts at various controlled ovarian stimulation (COS) protocols, a greater number of embryos or a higher quality of embryos have not been obtained in this patient population [1]. However, luteal phase stimulation and the development of whole embryo freezing technology have been proven to be safe due to their use in the fertility preservation of patients with cancer [1].

Based on the breakthrough of the follicular wave theory, COS protocols have been updated with luteal phase simulation protocols and, more recently, the DuoStim protocol (follicular and luteal phase stimulation during the same menstrual cycle). Random start protocols have also been used. At present, the DuoStim protocol is typically used to provide fertility preservation for patients with cancer. Its applications in POR are recent developments [2]. The rapid development of cryopreservation technology and the implementation of the whole embryo freezing strategy have allowed for the DuoStim protocol to eliminate the traditional COS-oocyte retrieval-embryo transfer procedure and achieve more favourable results [5, 6].

There is currently limited research on DuoStim for POR [7–16]. This may be due to the fact that the traditional COS protocol is preferred in more clinical practices, as DuoStim is time-consuming and costly. The cancellation rate of the DuoStim procedure is very high [17, 18].

Among the published reports of DuoStim, the inclusion criteria for POR vary, as some studies adopted the Bologna criteria, [19] while others used the researchers’ custom criteria for patient inclusion. There are some previous studies that compare the DuoStim protocol with the traditional COS protocol [7–9]. Although DuoStim does not show advantages in all evaluation indicators, most of these studies tend to have better reproductive outcomes for DuoStim. The number of eggs, metaphase II (MII) oocytes, and embryos in the cleavage stage and the rate of superior embryos is increased after the DuoStim protocol compared to the traditional COS protocol. Studies that compare the embryos obtained after the follicular phase stimulation (FPS) stage with those obtained after the luteal phase stimulation (LPS) stage in DuoStim have found that stimulation during the LPS stage results in a higher number of oocytes and embryos [10–16]. However, the standards for embryo evaluation data vary widely, and the conclusions of these studies are contradictory. For the preimplantation genetic testing for aneuploidy (PGT-A) population, the DuoStim protocol has a higher euploid blastocyst rate [9] than the traditional COS protocol, and the euploid blastocyst rate obtained at the FPS stage is higher than that obtained at the LPS stage [20]. These studies focus more on the comparison of the dosage of gonadotropin (Gn), days of Gn duration, and COS protocol. While studies have shown that different trigger medicines impact embryo quality, [21] the trigger medicines of the DuoStim protocol have not been compared.

As the DuoStim protocol includes whole embryo vitrification, it is particularly important to discuss the rate of good quality embryos obtained using this method [9]. Therefore, under the premise of Bologna’s inclusion criteria, this retrospective study compares the embryos obtained at the LPS stage with those obtained at the FPS stage through comprehensive embryo assessment data, and explores the impact of different trigger medications of the DuoStim protocol on embryo data for POR.

Methods

Study design and participants

Patients

This retrospective study reviewed the medical records of 304 women who were diagnosed as POR and underwent the DuoStim protocol at the Centre for Reproductive Medicine Department of Guangdong Women and Children Hospital for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) from January 2014 to February 2017. All patients in this study adhered to the Bologna criteria; they each satisfied at least two of the following criteria: advanced maternal age (≥40 years), a history of POR (≤3 oocytes with a conventional stimulation protocol), or abnormal ovarian reserve tests (i.e., antral follicle count <7 or antimullerian hormone <1.1 ng/mL) [19]. Exclusion criteria included the presence of known endometrial abnormalities, genetic abnormalities, and repeated implantation failure. The study protocol was approved by the institutional ethics committee of Guangdong Women and Children Hospital, and informed was obtained from each patient. This study was conducted in accordance with the principles of the Declaration of Helsinki.

IVF treatment and patient groups

As shown in Fig. 1, FPS was achieved with the administration of a gonadotropin (Gn), including recombinant follicle stimulating hormone (rFSH) or highly purified FSH (HP-FSH) and human menopausal gonadotropin (HMG). The initial dose of Gn ranged from 150 to 300 IU, depending on the basal follicle stimulating hormone (FSH) level, antral follicular count (AFC), and maternal age. The mild ovarian-stimulation regimen, which involves the timely addition of antagonists, was executed during FPS. When 1–3 dominant follicles reached 18–20 mm in diameter, the first trigger medicine was administered. Trigger medicines included urine human chorionic gonadotropin (uHCG; 10,000 IU), recombinant human chorionic gonadotropin (rHCG; 250 μg) and gonadotropin-releasing hormone agonist (GnRH-a; 0.2 mg). Oocytes were retrieved within 34 to 36 h of FPS. One day after the first cycle of oocytes were retrieved, a
vaginal ultrasound examination was performed. When the largest follicle diameter was < 10 mm and there were ≥ 2 follicles with diameters between 5 and 10 mm, patients were counselled regarding LPS. LPS was conducted by daily injections of HMG (225 IU). Daily administration of medroxyprogesterone acetate (MPA; 10 mg) was added to avoid oocyte retrieval during menstruation. Again, when 1–3 dominant follicles reached 18–20 mm in diameter, the second trigger medicine of the LPS phase was administered. Oocytes were retrieved within 34 to 36 h of LPS. We compared the data of the FPS phase with the data of the LPS phase in the same patients. Then, all patients were divided into three groups based on the trigger medicine used in FPS or LPS.

Embryo treatment
Good-quality embryos (Grade A: uniform or slightly uneven with fragmentation of < 10%; Grade B: uniform or non-uniform blastomere size, fragmentation of 10–20%) were frozen on day 3. The embryos that were not of good enough quality for cryopreservation were placed in extended culture until the blastocyst stage. At this stage, on day 5 or day 6, only blastocysts with good morphology were frozen. The embryo quality assessment on day 5 or day 6 was based on the scoring system of Gardner and Schoolcraft, with embryos graded as R3BB considered good blastocysts.

Frozen–thawed embryo transfer strategy
The frozen-thawed embryo transfer (FET) procedure for cleavage-stage embryos and blastocysts was used. Briefly, embryo vitrification was carried out with the Cyrotop carrier system, with dimethylsulfoxide–ethylene glycol–sucrose as a cryoprotectant. For thawing, embryos were transferred into a series of diluted sucrose solutions (1, 0.5, and 0 mol/L sucrose).

Serum β-HCG levels were measured 12–14 days after the transfer of embryos. Subsequent ultrasound examinations were performed at a gestational age of 7 weeks.

Outcome measurements
The main outcomes measured were the numbers of dominant follicles, oocytes retrieved, normal fertilised oocytes, cryopreserved embryos, and good quality embryos and blastocysts, as well as the rate of good quality embryos, cryopreserved embryos, and blastocysts, and the implantation and clinical pregnancy rates.

The oocyte yield was defined as the ratio of the total number of collected oocytes to the number of follicles measuring ≥10 mm on the day of oocyte retrieval. The fertilisation rate was defined as the ratio of normal fertilised oocytes (two pronuclei) to the number of oocytes used for fertilisation (for example, the denominator for calculating the fertilisation rate of IVF is all oocytes recovered, while it is the number of MII oocytes for ICSI). The rate of good quality embryos was calculated as the ratio of the number of good quality embryos and the total number of cleaved embryos with two pronuclei, expressed as a percentage. The rate of cryopreserved embryos was calculated as the ratio of the number of available embryos and the total number of cleaved embryos with two pronuclei, expressed as a percentage. The implantation rate was defined as the...

Fig. 1 Steps of ovarian stimulation with DuoStim protocol. Gn = Gonadotrophin, GnRH-ant = Gonadotropin-releasing hormone antagonist, HMG = human menopausal gonadotropin, MPA = medroxyprogesterone acetate, FPS = follicular phase stimulation, LPS = luteal phase stimulation, uHCG = urine human chorionic gonadotropin, rHCG = recombinant human chorionic gonadotropin alfafor, GnRH-a = Gonadotropin-releasing hormone agonist.
number of gestational sacs observed divided by the number of embryos transferred. A clinical pregnancy was defined as the identification of a gestational sac 2–3 weeks after the embryo transfer. Early miscarriage was defined as pregnancy ending before 12 weeks of gestation.

The blastocyst formation rate was defined as the number of blastocysts formed divided by the number of embryos cultured. The blastulation rate of embryos of lesser quality was defined as the number of blastocysts formed divided by the number of lesser quality embryos cultured. The pregnancy rate per oocyte retrieval was defined as the pregnancy cycle divided by the number of oocyte retrieval cycles (the number of oocyte retrieval cycles does not include the cycle of mixed embryo transfer or the cycle of unfertilised embryos).

Euploid rate analysis
Finally, among all 304 patients selected for enrolment, only 10 patients underwent the PGT-A cycle. We analysed the embryo euploidy rate of these 10 patients with PGT cycle.

Statistical analysis
The data were analysed using SPSS version 13 software. Continuous data are presented as an absolute mean with standard deviations (SD). Qualitative data are presented as percentages. The chi-squared test or Fisher's exact test were used to assess differences between categorical variables and the independent-samples t-test was used to assess differences between continuous variables. Differences in variables between the three trigger medicine groups was analysed using the chi-squared test or Fisher's exact test and a one-way ANOVA, as appropriate. Statistical significance was set at \( p < 0.05 \).

Results
Baseline cycle characteristics
In this retrospective study, a total of 304 IVF/ICSI cycles were investigated. The clinical features of the patients are shown in Table 1.

Comparison of the FPS and LPS stages
The comparison of the results of the FPS and LPS stages of the DuoStim protocol is shown in Table 2. The total dose of Gn administered during the LPS stage was higher than that in the FPS stage, and the duration of stimulation was longer. Oestrogen (E2), progesterone (P4), and luteinizing hormone (LH) levels measured during the LPS stage on the day that the trigger medicine was administered were higher than those in the FPS stage. The number of follicles at every size on the day that the trigger medication was administered during the LPS stage was significantly higher than that of the FPS stage. The numbers of oocytes retrieved, normal fertilised oocytes, cleaved embryos, cryopreserved embryos, and good quality embryos and the formed blastulation rate of the LPS stage were significantly higher than those of the FPS stage. However, the fertilisation rate, cleaved embryos rate, rate of cryopreserved embryos, and rate of good quality embryos were not significantly different between the two stages of the DuoStim protocol. Of the 304 patients included in this study, 53 patients were transplanted with embryos obtained from the FPS stage, and 110 were transplanted with embryos obtained from the LPS stage. The remaining 141 patients did not undergo embryo transplantation. The final pregnancy rates (including the pregnancy rate per FET and pregnancy rate per oocyte retrieval) and implantation rates obtained using embryos from the LPS stage were higher than those using embryos from the FPS stage. There was no significant difference in the rate of spontaneous abortion.

Outcomes of different trigger medicines used during the FPS stage
The patients were divided into three groups based on the first trigger medicine used in FPS: hCG \( (n = 178) \), rHCG \( (n = 101) \), and GnRH-a \( (n = 25) \) (Table 3). There were no significant differences in baseline characteristics of these groups, however, the total dose of Gn administered was significantly different. Also, there were no significant differences in the numbers of oocytes retrieved, fertilised oocytes, cleaved embryos, cryopreserved embryos, or good quality embryos between the three groups at the FPS stage. The fertilisation rates, cleaved embryos rates, rate of cryopreserved embryos, and good quality embryo rate were also not significantly different between the three groups, nor were the pregnancy rates, implantation rates, or spontaneous abortion rates at the FPS stage.

The outcomes of the LPS stage between the groups that received different trigger medicines during the FPS stage were also compared (Table 4). There were no significant differences in the numbers of oocytes retrieved, fertilised oocytes, cleaved embryos, cryopreserved embryos, or good quality embryos among the three groups. There were also no significant differences in the fertilisation rates or cleaved embryos rates. However, the rates of cryopreserved embryos and good quality embryos

| Maternal age (years) | Basal FSH (IU/L) | Basal LH (IU/L) | Basal E2 (pg/ml) | Basal AFC | BMI |
|---------------------|-----------------|----------------|-----------------|-----------|-----|
| 38.34 ± 4.85        | 10.17 ± 5.13    | 4.98 ± 2.31    | 48.67 ± 41.20   | 5.19 ± 4.25 | 22.56 ± 3.15 |

Values are noted as mean ± SD
BMI Body mass index, E2 estradiol, AFC antral follicle count
obtained in the LPS stage in patients who were first administered rHCG or GnRH-a during the FPS stage were significantly higher than those who were first administered uHCG during the FPS stage. There were no significant differences between patients who received rHCG and those who received GnRH-a during the FPS stage. There were no significant differences in the pregnancy rate, implantation rate, or spontaneous abortion rate among the three groups.

Outcomes of different trigger medicines used during the LPS stage
The patients were also divided into three groups based on the first trigger medicine used in LPS: uHCG (n = 196), rHCG (n = 93), and GnRH-a (n = 15) (Table 5). There were no significant differences in baseline characteristics among the three groups. Also, there were no significant differences in the numbers of oocytes retrieved, fertilised oocytes, cleaved embryos, cryopreserved embryos, or good quality embryos among the three groups. There were no significant differences in fertilisation rates or cleaved embryos rates, however, the rates of cryopreserved embryos and good quality embryos in the patients who received rHCG and GnRH-a first during the LPS stage were significantly higher than those in the patients who received uHCG first during the LPS stage. There was no significant difference between patients who received rHCG and patients who received GnRH-a. There was no significant difference between the three groups in the pregnancy rate, implantation rate, or spontaneous abortion rate.

Euploid rate analysis
Among the 304 POR patients, 10 patients underwent a PGT-A cycle, including 5 patients younger than 35 years old and 5 patients older than or equal to 35 years old. A total of 20 embryos were obtained from 10 patients, of which 8 embryos were from the FPS stage and 12 embryos were from the LPS stage. The proportions of aneuploid embryos in the FPS group and the LPS group were 75.00% (6/8) and 33.33% (4/12), respectively, and there was no statistical difference. The ratios of transferable embryos in the FPS group and LPS group were 25.00% (2/8) and

---

Table 2 Comparison of the FPS and LPS stage within DuoStim protocol

| Characteristic | FPS stage n = 304 | LPS stage n = 304 | P value |
|---------------|------------------|------------------|---------|
| Total dose of Gonadotrophin (IU) | 1359.51 ± 1135.84 | 1678.25 ± 882.64* | 0.000 |
| Duration of stimulation (days) | 6.10 ± 3.48 | 7.16 ± 3.12* | 0.000 |
| E2 on HCG day (pg/ml) | 669.27 ± 527.86 | 1377.95 ± 1155.53* | 0.000 |
| P4 on HCG day (ng/ml) | 0.63 ± 0.95 | 14.98 ± 14.35* | 0.000 |
| LH on HCG day (IU/L) | 5.75 ± 5.50 | 3.94 ± 4.80* | 0.000 |
| Follicles ≥ 14 mm on HCG day | 1.46 ± 0.85 | 3.27 ± 2.94* | 0.000 |
| Follicles 10-13 mm on HCG day | 0.61 ± 1.01 | 1.39 ± 2.06* | 0.000 |
| Follicles ≤ 10 mm on HCG day | 2.07 ± 1.47 | 4.66 ± 4.49* | 0.000 |
| No. of oocyte retrieved | 1.71 ± 1.30 | 3.58 ± 4.54* | 0.000 |
| No. of normal fertilized oocyte | 1.09 ± 0.91 | 2.25 ± 2.85* | 0.000 |
| No. of cleaved embryos | 1.05 ± 0.91 | 2.20 ± 2.80* | 0.000 |
| No. of cryopreserved embryos | 0.90 ± 0.78 | 1.82 ± 2.54* | 0.000 |
| No. of good quality embryos | 0.79 ± 0.76 | 1.62 ± 2.40* | 0.000 |
| Fertilization rate (%) | 62.43% | 62.50% | 0.978 |
| Cleaved embryos rate (%) | 98.77% | 98.24% | 0.531 |
| Rate of cryopreserved embryos (%) | 85.93% | 82.63% | 0.188 |
| Rate of good quality embryos (%) | 74.69% | 73.80% | 0.766 |
| Formed blastulation rate (%) | 48.48% | 67.42%* | 0.037 |
| Lesser quality embryos formed blastulation rate (%) | 23.08% (3/13) | 32.08% (17/53) | 0.527 |
| Pregnancy rate per FET (%) | 26.42% (14/53) | 47.27% (52/110)* | 0.011 |
| Pregnancy rate per oocyte retrieval (%) | 7.37% (14/190) | 24.41% (52/213)* | 0 |
| Implantation rate (%) | 14.48% (21/145) | 29.81% (79/265)* | 0.001 |
| Spontaneous abortion rate (%) | 42.85% (6/14) | 21.15% (11/52) | 0.099 |

Data are presented as number (%) unless otherwise indicated. Independent t-test was used to compare continuous variables, and Chi-squared test or Fisher’s exact test for categorical ones.

*Compared with FPS Group, P < 0.05
58.33% (7/12), respectively, and there was no statistical difference (Table 6).

**Discussion**

We found that the numbers of oocytes retrieved, normal fertilised oocytes, cleaved embryos, cryopreserved embryos, and good quality embryos during the LPS stage are significantly higher than those during the FPS stage in POR patients undergoing the DuoStim protocol. We also found that the trigger medicines used during the FPS stage did not affect the outcomes of that stage. The rates of cryopreserved embryos and good quality embryos resulting from the use of rHCG and GnRH-a as trigger medicines were significantly higher than those obtained when uHCG was used as a trigger medicine.

Overall, the number of oocytes obtained and the rate of good quality embryos were higher in the LPS stage than in the FPS stage. This is consistent with previous studies [10–16]. Embryos obtained at the LPS stage may result in more favourable outcomes due to several factors. The high oestrogen and progesterone levels of the LPS stage may result in more synchronous follicular development and promote the proliferation of FSH receptors in granular cells [20]. Animal studies have reported that high oestrogen and progesterone levels at the LPS stage may lead to an increase in angiogenic factors, thereby promoting the sensitivity of granulocytes to FSH [22]. Another study found no significant differences in the miRNA of the follicular fluid in patients at the LPS and FPS stages, however, this study requires verification due to the limitations of the miRNA detection screening index and its limited sample size [23]. No differences have been reported in the final neonatal birth defect rate in embryos obtained during the FPS or LPS stage [24]. Taken together, the results of these studies suggest that obtaining oocytes at the LPS stage results in a higher number of embryos, however, future studies are required to confirm this conclusion.

When GnRH-a was administered as a trigger medicine, the rate of good quality embryos was higher, regardless of whether it was administered during the FPS or LPS stage. This may be explained by the fact that GnRH-a has a smaller flare up effect, which can improve the synchronisation of follicular development [25]. The flare up effect of GnRH-a will results in a slight increase in endogenous FSH levels, which may promote the growth of follicles with a diameter of 4 mm or less. At the same time, the elevated FSH concentration is lower

**Table 3** Comparison of outcomes at FPS stage of different trigger medicine at FPS stage

| Characteristic                  | uhCG 10,000 IU | rhCG 250 μg | GnRha 0.2 mg | P value |
|--------------------------------|---------------|------------|-------------|---------|
| Number                         | 178           | 101        | 25          |         |
| AFC                            | 5.30 ± 4.19   | 5.57 ± 4.80| 3.96 ± 2.52 | 0.248   |
| FSH (IU/L)                     | 10.22 ± 5.51  | 9.88 ± 4.71| 9.88 ± 3.12 | 0.841   |
| Maternal age (years)           | 38.30 ± 5.11  | 38.0 ± 4.92| 38.04 ± 5.67| 0.884   |
| Total dose of gonadotrophin (IU)| 1524.27 ± 1298.85| 1183.04 ± 813.58| 906.00 ± 747.78| 0.006   |
| Duration of stimulation (days) | 6.42 ± 3.70   | 5.98 ± 3.16| 4.24 ± 2.59 | 0.012   |
| follicle of >10 mm on HCG day  | 2.06 ± 1.44   | 2.18 ± 1.64| 1.71 ± 0.62 | 0.367   |
| No. of oocyte retrieved        | 1.73 ± 1.30   | 1.72 ± 1.37| 1.48 ± 0.96 | 0.66    |
| No. of normal fertilized oocytes| 1.13 ± 0.87   | 1.03 ± 1.00| 1.08 ± 0.78 | 0.669   |
| No. of cleaved embryos         | 1.08 ± 0.88   | 1.01 ± 1.00| 1.00 ± 0.82 | 0.773   |
| No. of cryopreserved embryos   | 0.93 ± 0.80   | 0.87 ± 0.77| 0.84 ± 0.62 | 0.745   |
| No. of good embryos            | 0.80 ± 0.78   | 0.76 ± 0.75| 0.80 ± 0.65 | 0.929   |
| Fertilization rates (%)         | 63.64%        | 58.62%     | 70.27%      | 0.327   |
| Cleaved embryos rates (%)      | 98.47%        | 100%       | 96.15%      | 0.238   |
| Rate of cryopreserved embryos (%)| 86.01%        | 86.27%     | 84.00%      | 0.957   |
| Rate of good embryos (%)       | 73.58%        | 75.49%     | 80.00%      | 0.766   |
| the pregnancy rate per oocyte retrieval (%)| 8.03%(9/112) | 6.35%(4/63) | 6.67%(1/15) | 0.914   |
| Pregnancy /FET (%)             | 29.03%(9/31) | 22.22%(4/18)| 25.00%(1 / 4)| 0.871   |
| Implantation rate (%)          | 16.00%(12/75) | 13.79%(8 /58)| 8.33%(1 /12)| 0.768   |
| Spontaneous abortion rate (%)  | 44.44%(4/9)   | 50.00%(2/4) | 0.00%(0/1)  | 0.656   |

Data are presented as number (%) unless otherwise indicated. Independent t-test was used to compare continuous variables, and Chi-squared test or Fisher’s exact test for categorical ones.

*Compared with uhCG 10,000 IU Group, P < 0.05
than the threshold that allows periodic follicle recruitment, rendering follicles with a diameter of 7.5–10 mm unable to begin to develop. GnRH-a may also regulate the cascade of follicular development events before follicles mature [26, 27]. The local regulation factors influenced by GnRH-a include anti-Mullerian hormone (AMH) and inhibin B, which are secreted by granulocytes. AMH inhibits the initiation of primitive follicular growth in the ovarian reserve. In contrast to AMH, all follicles produce inhibin B, which helps reduce FSH prior to follicular maturity [28]. However, these hypotheses have yet to be confirmed, and the role of endocrine and paracrine factors in the mechanism of follicle recruitment that regulates the growth of the anovulatory tide in the ovarian cycle requires further investigation.

The advantages of rHCG as a trigger drug observed in this study were not anticipated by our team. rHCG is an HCG preparation extracted from Chinese hamster ovary cells using recombinant technology [29, 30]. Compared with uHCG extracted from pregnant women’s urine, rHCG is more pure, has a higher batch-to-batch consistency, and can be injected subcutaneously [31, 32]. In addition, because rHCG is not available in all countries, its pharmacology, pharmacokinetics, and the differences after application to patients of different races are unknown. A Japanese study showed that the potential differences in the pharmacokinetic profiles of rHCG between Japanese and Caucasian patients cannot be ignored [33].

It has been reported that the number of oocytes retrieved per patient and the clinical pregnancy rates resulting from the use of the GnRH-a long protocol, as in COS, were similar when rHCG and uHCG were used [34, 35]. rHCG has been reported to have lower incidences of injection site reactions (such as redness and swelling) than uHCG, which may be attributed to fewer contaminating proteins in rHCG. In addition, a reduction in patient complaints of redness and swelling were observed after uHCG was switched to rHCG [37]. Therefore, the use of rHCG or GnRH-a as a trigger medicine in the FPS stage of the DuoStim protocol maybe better than the use of uHCG. However, more clinical and pharmacological research will be needed to determine more benefits of the use of rHCG and GnRH-a in the DuoStim protocol.

Our study has a unique design. First, we used an antagonist regimen in the follicular phase and a progesterone-primed ovarian stimulation (PPOS) regimen in the luteal phase to prevent the surge of the LH peak. There has been controversy about whether the use of MPA in the PPOS scheme [38]. It is suggested that the numbers of blastocysts and euploid blastocysts

| Characteristic                  | uHCG 10,000 IU n = 178 | rHCG 250 μg n = 101 | GnRH-a 0.2 mg n = 25 | P value |
|--------------------------------|-------------------------|---------------------|----------------------|---------|
| AFC                            | 5.10 ± 4.00             | 5.33 ± 4.83         | 4.29 ± 2.51          | 0.552   |
| FSH (IU/L)                     | 10.33 ± 5.47            | 9.99 ± 4.78         | 10.81 ± 4.77         | 0.759   |
| Maternal age (years)           | 38.41 ± 5.08            | 37.98 ± 4.96        | 38.08 ± 5.64         | 0.784   |
| Total dose of Gn (IU)          | 1619.52 ± 813.79        | 1695.50 ± 820.23    | 2027.40 ± 1410.64    | 0.093   |
| Duration of stimulation (days) | 6.97 ± 2.89             | 7.21 ± 2.95         | 8.32 ± 4.84          | 0.127   |
| FSH of >10 mm on HCG day       | 4.65 ± 4.08             | 4.78 ± 5.40         | 4.28 ± 3.29          | 0.884   |
| No. of oocyte retrieved        | 3.61 ± 3.85             | 3.64 ± 5.88         | 3.08 ± 2.41          | 0.848   |
| No. of fertilized oocytes      | 2.31 ± 2.26             | 2.19 ± 3.88         | 2.12 ± 1.62          | 0.923   |
| No. of cleaved embryos         | 2.25 ± 2.21             | 2.14 ± 3.81         | 2.08 ± 1.58          | 0.931   |
| No. of cryopreserved embryos   | 1.78 ± 1.89             | 1.90 ± 3.57         | 1.76 ± 1.30          | 0.918   |
| No. of good quality embryos    | 1.56 ± 1.79             | 1.72 ± 3.36         | 1.64 ± 1.29          | 0.865   |
| Fertilization rates (%)         | 63.45%                  | 59.51%              | 68.83%               | 0.227   |
| Cleaved embryos rates (%)      | 98.04%                  | 98.63%              | 98.11%               | 0.864   |
| Rate of cryopreserved embryos  | 79.00%                  | 88.89%*             | 84.62%*              | 0.008   |
| Rate of good quality embryos   | 69.50%                  | 80.56%*             | 78.85%*              | 0.008   |
| Pregnancy rate per oocyte retrieval (%) | 26.23%/32/122   | 20.00%/14/70        | 28.57%/6/21          | 0.562   |
| Pregnancy rate per FET (%)     | 46.38%/32/69            | 48.28%/14/29        | 50.00%/6/12          | 0.966   |
| Implantation rate (%)          | 27.84%/49/176           | 33.90%/20/59        | 33.33%/10/30         | 0.614   |
| Spontaneous abortion rate (%)  | 21.88%/7/32             | 14.29%/2/14         | 33.33%/2/6           | 0.625   |

Data are presented as number (%) unless otherwise indicated. Independent t-test was used to compare continuous variables, and Chi-squared test or Fisher’s exact test for categorical ones.

*Compared with uHCG 10,000 IU Group, P < 0.05.
per patient and the number of euploid embryos per injected oocyte are similar for patients undergoing the PPOS program and for those undergoing COS with GnRH antagonists [39]. Flexible progestin-primed ovarian stimulation (FPPOS) with MPA seems to be an effective choice for preventing premature ovulation in women undergoing ovarian stimulation without compromising oocyte quality [40]. Kuang et al. demonstrated that PPOS had a more robust control for preventing the premature rise of LH than GnRH antagonists in poor responders. Moreover, the comparison of the data in our article suggests that the ratio of available embryos and quality embryos for FPS and LPS is not statistically significant.

We used different types of Gn in the follicular and luteal phases. As the DuoStim scheme for COS has relatively little literature support, the Gn selected by different studies, especially the Gn in the luteal phase, are not consistent [12, 41]. We have not found evidence in the literature to support the use of different types of Gn in different follicular waves. The use of different types of Gn in different follicular waves requires further investigation. The DuoStim program has a high cycle cancellation rate during the implementation process, which may be due to the patient’s own personal reasons or the lack of a second follicular wave development in the luteal phase. Therefore, we used HMG in the luteal phase as it is more economical than rFSH. In addition, studies suggest that although rFSH may be administered at a lower dosage over fewer days during ovulation induction, the resulting pregnancy rate is not better than that of HMG [20, 42]. We believe that it is

Table 5 Comparison of outcomes at LPS stage of different trigger medicine at LPS stage of DuoStim protocol

| Characteristic                  | uhCG     | rhCG     | GnRha    | P value |
|--------------------------------|----------|----------|----------|---------|
| Number                         | 196      | 93       | 15       |         |
| AFC                            | 4.89 ± 3.89 | 5.62 ± 4.89 | 4.87 ± 3.44 | 0.385   |
| FSH (IU/L)                     | 10.14 ± 4.93 | 10.18 ± 5.35 | 12.22 ± 7.06 | 0.321   |
| Maternal age (years)           | 38.20 ± 4.83 | 38.10 ± 5.49 | 39.67 ± 5.70 | 0.531   |
| Total dose of gonadotrophin (IU) | 1633.29 ± 854.97 | 1791.68 ± 932.68 | 1570.00 ± 918.76 | 0.325   |
| Duration of stimulation (days) | 7.04 ± 2.94 | 7.47 ± 3.37 | 6.93 ± 3.81 | 0.527   |
| follicle of >10 mm on HCG day   | 4.32 ± 4.07 | 5.38 ± 5.38 | 4.69 ± 3.17 | 0.176   |
| No. of oocyte retrieved        | 3.39 ± 4.32 | 4.08 ± 5.17 | 2.93 ± 2.71 | 0.419   |
| No. of fertilized oocytes      | 2.16 ± 2.79 | 2.48 ± 3.14 | 1.93 ± 1.58 | 0.614   |
| No. of cleaved embryos         | 2.11 ± 2.74 | 2.45 ± 3.08 | 1.80 ± 1.42 | 0.531   |
| No. of cryopreserved embryos   | 1.61 ± 2.38 | 2.27 ± 2.93 | 1.67 ± 1.35 | 0.118   |
| No. of good embryos            | 1.43 ± 2.31 | 2.03 ± 2.68 | 1.67 ± 1.35 | 0.138   |
| Fertilization rates (%)         | 63.16%    | 60.95%    | 65.91%    | 0.694   |
| Cleaved embryos rates (%)      | 98.33%    | 98.70%    | 93.10%    | 0.095   |
| Rate of cryopreserved embryos (%) | 76.51%  | 92.54%*   | 92.59%    | 0       |
| Rate of good embryos (%)       | 67.55%    | 82.89%*   | 92.59%*   | 0       |
| Pregnancy rate per oocyte retrieval (%) | 24.63% (33/134) | 27.27% (18/66) | 7.69% (1/13) | 0.322   |
| Pregnancy /FET (%)             | 47.76% (32/ 67) | 54.20% (19/ 35) | 12.5% (1/ 8) | 0.101   |
| Implantation rate (%)          | 28.25% (50/177) | 37.33% (28/75) | 7.69% (1 /13) | 0.072   |
| Spontaneous abortion rate (%)  | 18.75% (6 /32) | 21.05% (4/19) | 100.00% (1/ 1) | 0.147   |

Data are presented as number (%) unless otherwise indicated. Independent t-test was used to compare continuous variables, and Chi-squared test or Fisher’s exact test for categorical ones.

*Compared with uhCG 10,000 IU Group, P < 0.05

Table 6 Euploid rate analysis

| Characteristic                  | FPS group | LPS group | t/c^2 value | P value |
|--------------------------------|-----------|-----------|-------------|---------|
| number                         | 4         | 6         |             |         |
| Proportion of patients≥35 years old | 50%(2/4) | 50%(3/6) | 0           | 1       |
| Aneuploid embryo rate           | 75.00%(6/8) | 33.33%(4/12) | 3.333      | 0.068   |
| Chromosome mosaicism embryo rate | 0.00%(0/8) | 8.33%(1/12) | 0.702      | 0.402   |
| Transferable embryo rate        | 25.00%(2/8) | 58.33%(7/12) | 2.155      | 0.142   |

Data are presented as number (%). Chi-squared test or Fisher’s exact test was used for categorical variables.
safe and economical to use HMG as a Gn drug during the luteal phase.

We also compared the aneuploidy rate of embryos in POR patients after DuoStim protocol, although the number of cases was limited. As the maternal age increases, the probability of abnormal meiosis during oogenesis or abnormal mitosis after fertilization is significantly increased, and the chance of complete chromosome deletion or addition in the embryo is increased [43, 44]. The incidence of chromosome abnormalities increases from 25% in women around the age of 20 to 65% in women over the age of 40 [45, 46]. However, whether maternal age is related to the risk of fragmented sex chromosome deletion or addition in embryos is still inconclusive, and requires confirmation by a large study. One study analysed the biopsy results of 15,169 blastocysts from women of different ages, and found that the incidence of aneuploidy in women aged 26 to 30 was the lowest, and the proportion of aneuploidy embryos increased significantly after the age of 35 [46]. Aneuploidy is an important factor in the failure of assisted pregnancy and spontaneous abortion in women with advanced maternal age. However, despite the limited sample size in this study, we found that the developmental potential of LPS and FPS embryos are similar. LPS embryos are not affected by high progesterone levels. This is consistent with the results of previous studies [2, 20].

The ESHRE (the european society of human reproduction and embryology) states that the DuoStim protocol should be used only for research. However, we believe that DuoStim can be safely and effectively used in patients who are POR. Their suggestion may be based on the safety of the DuoStim protocol. Baerwald et al. has proposed three theories of follicle recruitment [28], the theory of continuous recruitment, single recruitment theory, and the wave theory. The theory of continuous recruitment includes the interval between two ovulations [47]. During this time, the follicles begin to grow continuously and gradually disappear, and the dominant follicle is randomly selected after the corpus luteum has degenerated. The single recruitment theory involves a single group of follicles that start to grow after the corpus luteum degenerates, among which the dominant follicle is selected. The wave theory includes at least two groups of sinus eggs that are recruited. In each ovarian cycle, the dominant follicle originates only from the main (or ovulation) wave. There is no correlation between the average capacity of each patient’s MII oocytes recruited from the follicular phase and the luteal phase of the same follicular cycle, indicating that the two cohorts are independent. In addition, euploid blastocysts may be produced at any of the two stages of the ovarian cycle, which suggests that non-dominant follicles may be capable and will develop in a random manner. In other words, the advantages of the follicle may not automatically reflect its function. Therefore, we believe that the DuoStim protocol has advantages in POR patients, and there are no reports of safety concerns. The DuoStim protocol can be used as a method for COS in POR patients, however, further research is required to determine the feasibility of this expensive protocol.

The adverse reactions and complications of the accumulation of a high number of oocytes in a relatively narrow cycle time during the DuoStim protocol [48], and the short-term and long-term effects on the patient and the embryos require additional research. The length of time between the two stimulation schemes is very short, and the biological markers and microenvironment stability of the twice-obtained oocytes remain to be studied. The physiological aspects of the follicle recruitment theory also require further research. A comparison of the transcription and microenvironment aspects of the follicular fluid of the FPS and LPS stages, and an evaluation of the follicular fluid of embryos obtained at the LPS stage after different trigger schemes should be performed. Single and double trigger schemes should also be compared.

This is the first study to investigate the effects of the trigger medicine on oocyte retrieval in the DuoStim protocol. However, our study is not without limitations. This is a retrospective study and the sample size is limited. Comparing our results to those of previous studies is challenging due to the diversity of COS protocols.

**Conclusions**

Obtaining more and higher-quality oocytes and embryos in a short period of time while shortening the pregnancy time is crucial for POR patients. The high oocyte retrieval of the DuoStim protocol is suitable for patients who need to accumulate embryos, such as patients with cancer. The administration of GnRH-a or rHCG as the trigger medicine may be better than uHCG during both the FPS and LPS stages for POR undergoing the DuoStim protocol. We found that the number of oocytes obtained in the LPS stage was greater than that in the FPS stage.

**Abbreviations**

POR: Poor ovarian responder; ART: Assisted reproduction technology; COS: Controlled ovarian stimulation; MII: Metaphase II; FPS: Follicular phase stimulation; LPS: Luteal phase stimulation; PGT-A: Preimplantation genetic testing for aneuploidy; Gn: Gonadotropin; IVF: In vitro fertilisation; ICSI: Intracytoplasmic sperm injection; rFSH: Recombinant follicle stimulating hormone; HP-FSH: Highly purified FSH; HMG: Human menopausal gonadotropin; FSH: Follicle-stimulating hormone; AFC: Antral follicular count; uHCG: Urine human chorionic gonadotropin; rHCG: Recombinant human chorionic gonadotropin; GnRH-a: Gonadotropin-releasing hormone agonist; MPA: Medroxyprogesterone acetate; E2: Oestrogen; P4: Progesterone; LH: Luteinizing hormone; AMH: Anti-Mullerian hormone; PPOS: Progesterone-primed ovarian stimulation; FPPOS: Flexible progestin-primed ovarian stimulation; ESHRE: The european society of human reproduction and embryology
Acknowledgements
We thank Junjian He for his spiritual encouragement and support during the difficult resubmission process. We are also very grateful for Qianyu Zhang's companionship and feeding throughout the process.

Authors’ contributions
Liu, FH designed the study and revised the manuscript. Luo, YQ and Sun, L drafted the manuscript, designed the study and performed the statistical analysis. Nong, YQ and Dong, M helped to draft the manuscript. Zhu, XL analyzed the data. Zhang, XQ participated in the design of the study. Huang, L helped to analyze the data. All authors read and approved the final manuscript.

Funding
The whole study was supported by Natural Science Foundation of Guangdong Province (No. 2016A030313817) and Science and Technology Program of Guangzhou, China (201704020217).

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Guangdong Women and Children Hospital and has been performed in accordance with the principles of Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1The First Affiliated Hospital of Jinan University, 613 Huangpu Avenue West, Tianhe District, Guangzhou 510630, Guangdong Province, China.
2Department of Reproductive Medical Center, Guangdong Women and Children Hospital, No. 521 Xingnan Road, Guangzhou 511400, Guangdong Province, China.

Received: 28 March 2020 Accepted: 24 September 2020

References
1. Labarta E. DuoStim: a new strategy proposed for women with poor ovarian response. Fertil Steril. 2020;113:76–7.
2. Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017;23:211–20.
3. Yang DZ, Yang W, Li Y, He Z. Progress in understanding human ovarian folliculogenesis and its implications in assisted reproduction. J Assist Reprod Genet. 2013;30:213–9.
4. Cobo A, Garrido N, Crespo J, Jose R, Pellicer A. Accumulation of oocytes: a new strategy for managing low-responder patients. Reprod BioMed Online. 2012;24:424–32.
5. Vaiairelli A, Cimadomo D, Ubaldi N, Renzi L, Ubaldi FM. What is new in the management of poor ovarian response in IVF? Curr Opin Obstet Gynecol. 2018;30:153–62.
6. Vaiairelli A, Venturella R, Vizziello D, Bulletti F, Ubaldi FM. Dual ovarian stimulation and random start in assisted reproductive technologies: from ovarian biology to clinical application. Curr Opin Obstet Gynecol. 2017;29:153–9.
7. Jin B, Niu Z, Xu B, Chen Z, Zhang A. Comparison of clinical outcomes among dual ovarian stimulation, mild stimulation and luteal phase stimulation protocols in women with poor ovarian response. Gynecol Endocrinol. 2018;34:694–7.
8. Madani T, Hesam M, Arabpoor A, Khodabakhshi SH, Zolfaghari Z. Double mild stimulation and egg collection in the same cycle for management of poor ovarian responders. J Gynecol Obstet Hum Reprod. 2019;48:329–33.
9. Vaiairelli A, Cimadomo D, Conforti A, Schibienmeli M, Giuliani M, D’Alejandro P, Colamaria S, Alviggi C, Renzi L, Ubaldi FM. Luteal phase after conventional stimulation in the same ovarian cycle might improve the management of poor responder patients fulfilling the Bologna criteria: a case series. Fertil Steril. 2020;113:121–30.
10. Alsbjerg B, Haaftr T, Elbaek HO, Laursen R, Povlsen BB, Huumidayan P. Dual stimulation using conﬁDentropia alfa in S4 Bologna criteria poor ovarian responders - a case series. Reprod BioMed Online. 2019;38:677–82.
11. Bourdon M, Santulli P, Maignien C, Pocata-Cheret K, Marcellin L, Chen Y, Chapron C. The ovarian response after follicular versus luteal phase stimulation with a double stimulation strategy. Reprod Sci. 2020;27:204–10.
12. Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, Shoham Z. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod BioMed Online. 2014;29:694–91.
13. Liu C, Jiang H, Zhang W, Yin H. Double ovarian stimulation during the follicular and luteal phase in women >/=38 years: a retrospective case-control study. Reprod BioMed Online. 2017;35:678–84.
14. Rashiah J, Zhang L. Luteal-phase ovarian stimulation increases the number of mature oocytes in older women with severe diminished ovarian reserve. Syst Biol Reprod Med. 2018;64:216–9.
15. Ubaldi FM, Capalbo A, Vaiairelli A, Cimadomo D, Colamaria S, Alviggi C, Trabucco E, Venturella R, Vaja G, Renzi L. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation: new insight in ovarian reserve exploitation. Fertil Steril. 2016;105:1488–95 e1481.
16. Vaiairelli A, Cimadomo D, Trabucco E, Valleluko R, Buffo L, Dusi L, Fiorini F, Barnocchi N, Bulletti FM, Renzi L, Ubaldi FM. Double stimulation in the same ovarian cycle (DuoStim) to maximize the number of oocytes retrieved from poor prognosis patients: a multicenter experience and SWOT analysis. Front Endocrinol (Lausanne). 2018;9:317.
17. Ubaldi FM, Cimadomo D, Vaiairelli A, Fabozzi G, Venturella R, Maggirlli R, Mazzilli R, Ferrero S, Palagiano A, Renzi L. Advanced maternal age in IVF: still a challenge? The present and the future of its treatment. Front Endocrinol (Lausanne). 2019;10:94.
18. Vaiairelli A, Cimadomo D, Argento C, Ubaldi N, Trabucco E, Drakopoulos P, Venturella R, Conforti A, Alviggi C, Renzi L, Ubaldi FM. Double stimulation in the same ovarian cycle (DuoStim) is an intriguing strategy to improve oocyte yield and the number of competent embryos in a short timeframe. Minerva Ginecol. 2019;71:372–6.
19. Ferrariati AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. Definition EwipoPOR. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2012;26:1616–24.
20. Cimadomo D, Vaiairelli A, Colamaria S, Trabucco E, Alviggi C, Venturella R, Alviggi E, Carmelo R, Renzi L, Ubaldi FM. Luteal phase anovulatory follicles result in the production of competent oocytes: intra-patient paired case-control study comparing follicular versus luteal phase stimulations in the same ovarian cycle. Hum Reprod. 2018;33:1442–8.
21. Zhang J, Wang Y, Mao X, Chen Q, Hong Q, Cai R, Zhang S, Kuang Y. Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF/ICSI cycles. Reprod BioMed Online. 2017;35:701–7.
22. Macchiarelli G, Jiang JY, Nottola SA, Sato E. Morphological patterns of angiogenesis in ovarian follicle capillary networks: A scanning electron microscopy study of corrosion cast. Microsc Res Tech. 2006;69:459–68.
23. Cimadomo D, Carmelo R, Parrotta EI, Scalise S, Santamaria G, Alviggi E, De Angelis MT, Sarro G, Vaiairelli A, Venturella R, et al. Similar miRNomic signatures characterize the follicular fluids collected after follicular and luteal phase stimulations in the same ovarian cycle. J Assist Reprod Genet. 2020;37:149–58.
24. Chen H, Wang Y, Lyu Q, Ai A, Fu Y, Tian H, Cai R, Hong Q, Chen Q, Shoham Z, Kuang Y. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertil Steril. 2015;103:1194–201 e1192.
25. Wang S, Sun HX, Liu JY, Hu HJ, He FP. Appropriate prolongation of GnRH-a down-regulation improves the synchronism of follicular development. Zhong Hai Xue Nan Ke Xue. 2011;17:1087–91.
26. Nilsson E, Rogers N, Skinner MK. Actions of anti-Mullerian hormone on the ovarian transcriptome to inhibit primordial to primary follicle transition. Reproduction. 2007;134:209–21.
27. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. Anti-Mullerian hormone expression
pattern in the human ovary: potential implications for initial and cyclical follicle recruitment. Mol Hum Reprod. 2004;10:77–83.

28. Baenwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012;18:73–91.

29. Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, Zhu XP, Zhou Q. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015;9:923–42.

30. Thennati R, Singh SK, Nage N, Patel Y, Bose SK, Burade V, Rankhor RS. Analytical characterization of recombinant hCG and comparative studies with reference product. Biologics. 2018;12:23–35.

31. Chen CC, Ng EH, Tang OS, Yeung WS, Lau EY, Ho PC. A prospective, randomized, double-blind study to compare two doses of recombinant human chorionic gonadotropin in inducing final oocyte maturity and the hormonal profile during the luteal phase. J Clin Endocrinol Metab. 2005;90:3933–8.

32. van der Merwe R, Lugan I, Lecueille H, Papasouliotis O, Buraglio M. The bioequivalence of liquid and freeze-dried formulations of recombinant human chorionic gonadotrophin. Curr Med Res Opin. 2004;20:397–402.

33. Bagchus W, Wolna P, Uhl W. Single-dose pharmacokinetic study comparing the pharmacokinetics of recombinant human chorionic gonadotropin in healthy Japanese and Caucasian women and recombinant human chorionic gonadotropin and urinary human chorionic gonadotropin in healthy Japanese women. Reprod Med Biol. 2018;17:52–8.

34. Driscoll GL, Tyler JP, Hangart JT, Fisher PR, Birdsell MA, Knight DC. A comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod. 2000;15:1305–10.

35. Yousef MA, Abou-Setta AM, Lam WS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev. 2016;CD003719.

36. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG. The European Recombinant Human Chorionic Gonadotrophin Study Group. Hum Reprod. 2000;15:1446–51.

37. Nakagawa K, Oba M, Ebara K, Ishigaki N, Ino N, Itakura A, Tsutsumi R, Nakao K, Ojio Y, Sugiyama R. Clinical outcomes of assisted reproductive technology treatment by using a self-injection of recombinant human chorionic gonadotropin as the final maturation trigger. Reprod Med Biol. 2018;17:203–8.

38. Yildiz S, Turkoglu E, Angun B, Eraslan A, Defgin S, Ustunman B, Ata B. Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril. 2019;112:677–83.

39. Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X, Zeng X, Sun L, Huang Y. Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing in vitro Fertilization Treatment: A Randomized Controlled Trial. Front Endocrinol (Lausanne). 2019;10:796.

40. La Marca A, Capuzzo M, Sacchi S, Imbrogno MG, Spinella F, Vancichia MT, Minasi MG, Greco P, Fiorentino F, Greco E. Comparison of euploidy rates of embryos in women treated with progestins or GnRH antagonist to prevent the luteinizing hormone surge during ovarian stimulation. Hum Reprod. 2020;35:1325–31.

41. Al-Inany HG, Abou-Setta AM, Aboualghar MA, Mansour RT, Serour GI. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod BioMed Online. 2008;16:81–8.

42. Bosch E, Vidal C, Labarta E, Simon C, Remohi J, Pellicer A. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists—a randomized study. Hum Reprod. 2008;23:2346–51.

43. Babarya D, Fragouli E, Alfarawati S, Spath K, Wells D. The incidence and origin of segmental aneuploidy in human oocytes and preimplantation embryos. Hum Reprod. 2017;32:2549–60.

44. Demko ZP, Simon AL, McCoy RC, Petrov DA, Rabanowitz M. Effects of maternal age on euploidy rates in a large cohort of embryos analyzed with 24-chromosome single-nucleotide polymorphism-based preimplantation genetic screening. Fertil Steril. 2016;105:1307–13.

45. Fransasiak JD, Forman RJ, Hong KH, Werner MD, Upham KM, Threff NR, Scott RT Jr. The nature of aneuploidy with increasing age of the female partner: a review of 13,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril. 2014;101:656–63 e651.

46. Rubio C, Bellver J, Rodrigo L, Castillon G, Guillen A, Vidal C, Giles J, Ferrando M, Cabanillas S, Remohi J, et al. In vitro fertilization with preimplantation genetic diagnosis for aneuploidy in advanced maternal age: a randomized, controlled study. Fertil Steril. 2017;107:1122–9.

47. Sfakianoudis K, Pantos K, Grigorakis S, Rapani A, Maliotis E, Tsiloulo P, et al. What is the true place of a double stimulation and double oocyte retrieval in the same cycle for patients diagnosed with poor ovarian reserve? A systematic review including a meta-analytical approach. J Assist Reprod Genet. 2020;37(1):181–204.

48. Vaiarelli A, Cimadamore D, Petriglia C, Conforti A, Alkighi C, Ubaldi N, et al. DuoStim - a reproducible strategy to obtain more oocytes and competent embryos in a short time-frame aimed at fertility preservation and IVF purposes. A systematic review. Ups J Med Sci. 2020;125(2):121–30.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.